 The FDA has extended the review period for Bluebird bio Incs NASDAQ: BLUE biologics licensing applications BLA for its lentiviral vector gene therapies. The agency has pushed the applications for betibeglogene autotemcel beti-cel for β-thalassemia and elivaldogene autotemcel eli-cel for cerebral adrenoleukodystrophy CALD. 